

**Alteration of cardiac progenitor cell potency in GRMD dogs**

Running Header: CPCs from healthy and dystrophic dogs.

Cassano M<sup>1</sup>, Berardi E<sup>1</sup>, Crippa S<sup>1</sup>, Toelen J<sup>3</sup>, Barthelemy I<sup>2</sup>, Micheletti R<sup>1</sup>, Chuah M<sup>4</sup>,  
Vanderdriessche T<sup>4</sup>, Debyser Z<sup>3</sup>, Blot S<sup>2</sup> and Sampaolesi M<sup>1,5</sup>

<sup>1</sup> Laboratory of Translational Cardiomyology, Stem Cell Institute, Department of Development and Regeneration, Katholieke Universiteit Leuven, Herestraat 49 O&N1 bus 814, 3000 Leuven, Belgium; <sup>2</sup> Laboratoire de Neurobiologie, Ecole Nationale Vétérinaire d'Alfort, 94704 Maisons-Alfort, France; <sup>3</sup> Molecular Virology and Gene Therapy, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Belgium; <sup>4</sup> Free University of Brussels, Vesalius Research Center, Flanders Institute of Biotechnology (VIB) & University of Leuven, 3000 Leuven, Belgium; <sup>5</sup> Human Anatomy Institute, Department of Public Health, Neuroscience, Experimental and Forensic Medicine, University of Pavia, Via Forlanini 8, 27100 Pavia, Italy

Address correspondence to:

Maurilio Sampaolesi, Ph.D.

Laboratory of Translational Cardiomyology, Stem Cell Institute, Department of Development and Regeneration, Katholieke Universiteit Leuven, Herestraat 49 O&N1 bus 814, 3000 Leuven, Belgium

## ABSTRACT

Among the animal models of Duchenne Muscular Dystrophy (DMD), the Golden Retriever Muscular Dystrophy (GRMD) dog is considered the best model in terms of size and pathological onset of the disease. As in human patients presenting with DMD or Becker muscular dystrophies (BMD), the GRMD is related to a spontaneous X-linked mutation of dystrophin and is characterized by myocardial lesions. In this respect, GRMD is a useful model to explore cardiac pathogenesis and for the development of therapeutic protocols. To investigate whether cardiac progenitor cells (CPCs) isolated from healthy and GRMD dogs may differentiate into myocardial cell types, and to test the feasibility of cell therapy for cardiomyopathies in a pre-clinical model of DMD, CPCs were isolated from cardiac biopsies of healthy and GRMD dogs. Gene profile analysis revealed an active cardiac transcription network in both healthy and GRMD CPCs. However, GRMD CPCs showed impaired self-renewal and cardiac differentiation. Population doubling and telomerase analyses highlighted earlier senescence and proliferation impairment in progenitors isolated from GRMD cardiac biopsies. Immunofluorescence analysis revealed that only wt CPCs showed efficient although not terminal cardiac differentiation, consistent with the upregulation of cardiac-specific proteins and microRNAs. Thus, the pathological condition adversely influences the cardiomyogenic differentiation potential of cardiac progenitors. Using PiggyBac transposon technology we marked CPCs for nuclear dsRed expression, providing a stable non-viral gene marking method for *in vivo* tracing of CPCs. Xenotransplantation experiments in neonatal immunodeficient mice revealed a valuable contribution of CPCs to cardiomyogenesis with homing differences between wt and dystrophic progenitors. These results suggest that cardiac

degeneration in dystrophinopathies may account for the progressive exhaustion of local cardiac progenitors and shed light on cardiac stemness in physiological and pathological conditions. Furthermore, we provide essential informations that canine CPCs may be used to alleviate cardiac involvement in large preclinical model of DMD.

**Keywords:** cardiac progenitor, muscular dystrophy, GRMD model, cell therapy



## INTRODUCTION

Dystrophinopathies are a group of inherited diseases characterized by the absence of structural proteins of the dystrophin glycoprotein complex (DGC). Duchenne (DMD) and Becker muscular dystrophies (BMD) are caused by mutations in the dystrophin gene, which encodes for the largest protein in the DGC and primarily effects skeletal and cardiac muscle (13). Both DMD and BMD are associated with cardiac degeneration and morbidity leading to hypertrophic then/or dilated cardiomyopathy (2,36). The improvement of multidisciplinary patient care has increased life expectancy in DMD and BMD patients, however, heart failure is now the main cause of death (17,40,52). Thus, rescuing dystrophin expression in cardiac muscle has become more critical for the longevity and quality of life in DMD and BMD patients. Among the various animal models of DMD, the Golden Retriever Muscular Dystrophy (GRMD) dog is considered the best model in terms of size and pathology onset. The GRMD dog carries a point mutation in the splice acceptor site in intron 6 of the orthologous X-linked dystrophin gene (18), and has a clinical course very similar to that of human patients, characterized by progressive muscle wasting, degeneration, fibrosis and a shortened lifespan (3,22,27). Cardiac involvement in GRMD dogs has been demonstrated by electrocardiographic studies, with the onset of a progressive cardiomyopathy similar to DMD patients (10,38,54). In this respect, GRMD is a useful model to explore cardiac pathogenesis and for the development of new therapeutic protocols (56). Though considered the closest animal model to humans, the canine model has been poorly described in respect of stem cell therapy for chronic and acute cardiac diseases. More importantly, a recent study in dystrophic mice suggests that dystrophin restoration may exacerbate the failure of heart function if protein expression is not effectively restored in cardiac muscle (53). Recently, it has been demonstrated the presence of cardiac stem cells, including mesoangioblasts, from mice and

human cardiac biopsies are able to differentiate spontaneously *in vitro* and *in vivo* toward the cardiomyogenic lineages (19,20,29,31,37,39,41). To date, no comparative study has been performed to test the regenerative potential of these progenitors isolated from the dystrophic mice model. Here we describe the isolation of self-renewing cardiac progenitors (CPCs) from different regions of wild type and GRMD heart, capable of contributing to cardiovascular lineages in the post-natal forming heart. Under particular stimulation CPCs form smooth muscle, endothelial cells and immature cardiomyocytes, albeit with varying capacity. Interestingly, GRMD cardiac progenitors showed limited lifespan and proliferation deficiency compared to the wt counterpart.



## MATERIAL AND METHODS

### *Cell culture*

CPCs were isolated from cardiac muscle biopsies of GRMD and wild-type golden retrievers. GRMD and healthy dog colonies were maintained at the Veterinary School of Maisson-Alfort (Paris, France; see “*In vivo experiment*” section). Biopsies from different heart regions were kept in DMEM 10% fetal bovine serum (FBS) and separated by their regions of origin, namely aorta, atrium and ventricle. Most fragments contained small vessels (selected under microscope) and were transferred to a Petri dish coated with 1% gelatin or collagen in presence of 5% FBS MegaCell medium (Sigma-Aldrich, St.Louis, MO, US) supplemented with 5 ng/μL basic fibroblast growth factor (bFGF) plus 5 mM L-glutamine and antibiotics (Invitrogen, Carlsbad CA, US). These heart fragments were cultured for 8–12 days depending on the region and after the initial outgrowth of fibroblast-like cells, small round and refractile cells appeared. This cell population was easily collected by gently pipetting off the original culture, then counted and cultured in T75 flasks (Nunc, Rochester, NY US) using MegaCell medium. Single clones from each cardiac biopsy were obtained by serial dilution of 3 cells/96 well. Firstly, growing clones were selected morphologically and further analyzed as discussed in the result sections. Four clones from each cardiac biopsy (atrium, aorta and ventricle) were taken into account for the analysis. For cell culturing,  $10^3$  cells/cm<sup>2</sup> were plated in growing medium and incubated until they reach 75% confluency (usually  $4 \times 10^4$  cells/cm<sup>2</sup>). Population doubling (PD) time was calculated as the ratio  $\Delta t * (\log 2 / \log N_t - \log N_0)$ , where  $\Delta t$  = period time;  $N_t$  = number of cells at time  $t$ ;  $N_0$  = number of cells at time 0. For co-culture experiments, neonatal rat cardiomyocytes were isolated using the Neonatal CM isolation kit (Worthington Biochemical Corporation; Lakewood, NJ) according to the manufacturer’s protocol. Mouse myogenic cell line C2C12 was purchased from ATCC (LGC Standards

Middlesex, UK) and maintained in DMEM supplemented with 5 mM L-Glutamine and antibiotics (all from Invitrogen, Carlsbad, CA, USA) and 10% FBS (Lonza). Neonatal Rat Cardiomyocytes were cultured in DMEM 10% FBS (Invitrogen, Carlsbad, CA, USA). All cultures were incubated at 37°C in a humidified incubator with 5% CO<sub>2</sub> and 95% air. Cells were transduced with third generation lentiviral vector expressing green fluorescent protein (GFP) under the control of human Phosphoglucokinase (hPGK) promoter as previously described (39). For GFP<sup>+</sup> enrichment, ventricle (Ven) CPCs were sorted as described in the next section.

#### *Transfection and Fluorescence Activated Cell Sorting (FACS)*

For transfection,  $1.5 \times 10^5$  canine CPCs were transfected with 1 µg of pCMV-SPORT6/hNkx2.5 (cytomegalovirus vector containing human NK2 homeobox 5) using Effectene reagent (Qiagen, Valencia, CA, US) according to manufacturer's protocol. For transposon experiments, Nucleofection (Lonza, Rockland, ME, USA) was used for transfecting  $1 \times 10^6$  ventricle CPCs in T75 flasks. Each cell population was transfected with 6 µg of dsRed-containing transposon and 12 µg of transposase vectors derived from the PiggyBac system. For dsRed<sup>+</sup> positive enrichment,  $10^7$  transposon-transfected Ven CPCs were sorted for dsRed detection by flow cytometry (BD FACSDiva Option).

#### *Immunofluorescence and Western Blot analysis*

For immunocytochemistry, clones were washed with PBS and fixed with 4% paraformaldehyde (PFA) for 10 min. Cells were then stained with antibodies against different molecules overnight at 4°C and detected using species-specific secondary antibodies. Nuclei were counterstained with DAPI (Sigma-Aldrich, St.Louis, MO, US). For tissue histology, mice previously injected with  $2.5 \times 10^5$  Ven wt or GRMD canine CPCs were sacrificed and

hearts were quickly frozen in OCT (Sakura Finetek Tissue-Tek, Torrance, CA, USA). Serial heart sections were fixed with 4% PFA, permeabilized with 0.1% Triton-X100, rinsed with 1% bovine serum albumin (BSA) in PBS and immunostained with anti-dsRed, anti-cMyHC ( $\beta$ -cardiac myosin heavy chain) and anti- $\alpha$ SA (Sarcomeric Alpha Actinin). Alexa 488 or 594 (Molecular Probes, Eugene, OR, USA) were used as secondary staining Ig and DAPI was used for nuclear staining. For western blot analysis, cell pellets were suspended in a lysis buffer (pH 7.5) containing 50 mM Hepes, 150 mM NaCl, 100 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 0.5% Triton-X100, 0.5% Nonidet P-40 (NP-40), 1 mM dithiothreitol and 10% glycerol and supplemented with a protease inhibitor cocktail (Roche). Whole cell lysates or tissue extracts were then centrifuged at  $17,000 \times g$  for 10 min at 4°C to remove cell debris. Protein extracts (20–30  $\mu$ g) were electrophoresed on 10% sodium dodecyl sulfate (SDS) polyacrylamide gels under reducing conditions and subsequently transferred onto Immobilon-P membranes (Millipore Chemicon, MA, US) with a semi-dry blotting apparatus (BioRad, Herts, UK). The membranes were blocked in a 5% skim milk Tris-buffered saline-tween 20 solution (TBST) and subsequently probed with various antibodies. The membrane was washed with TBS-T and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (goat anti-mouse IgG or anti-rabbit IgG antibodies from Santa Cruz) for 30 min. Following further wash steps, the protein bands were visualized by enhanced chemiluminescence (Amersham, GE Healthcare, Diegem, BE) using a Fuji Scanner. Phase contrast images were taken with an inverted fluorescence microscope Nikon ECLIPSE TS-100. Immunofluorescence staining analysis was performed using Nikon ECLIPSE Ti-S inverted microscope. Confocal images were taken with Leica TCS SPE or with an inverted deconvolution microscope (DeltaVision RT) for the paneling images. Image editing was performed using “ImagePro” software provided by Nikon.



### *Cellular biochemistry*

For alkaline phosphatase (AP) staining, cultured plates or explants were rinsed with PBS fixed in 4% formaldehyde and stained for 1 hour in a 0.1M Tris-HCl solution (pH 8.5) containing 0.2 mg/ml of Naphthol AS-MX phosphate and 0.6 mg/ml of Fast Blue BB salt (Sigma-Aldrich, St.Louis, MO, US). For telomerase analysis, cell pellets at early, mid and late doublings were harvested and telomerase activity was measured using TRAPeze RT Telomerase Detection Kit (Millipore Chemicon, MA, USA). Briefly, cell lysates were obtained using CHAPS (3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate) lysis buffer and normalized. Following qPCR with specific Amplifluor primers, average Ct values of each sample were plotted to determine the log copy number of telomeres and relative telomerase activity values. For proliferation assays, at day 0,  $10^5$  cells from each cell population were seeded in MegaCell medium. At different time points cells were counted in triplicates using a haemocytometer and split according to their confluency. For more details about culturing, see “*Cell culture*” section. Wt or GRMD Ven CPCs were grown in DMEM 20% FBS without any cytokines. Two days after culture, media was analyzed for bFGF and vascular endothelial growth factor (VEGF) secretion using the Human FGF-Basic and VEGF Mini ELISA Development Kit from Peprotech according to the manufacturer’s protocols (Peprotech, Rocky Hill, NJ, USA). Plates were analyzed using the Model 680 Microplate Reader (BioRad, Herts, UK)

### *Reagents*

Antibodies used in the study are listed in *Table 1A*. Nuclei were stained with DAPI from Sigma (Sigma-Aldrich, St.Louis, MO, US). For endothelial differentiation, fluorescent-labeled human acetylated low density lipoprotein (acLDL) was purchased from Bti

(Biomedical Technology Inc. Stoughton, MA, US). Neonatal canine heart extracts were purchased from Gentaur (Kampenhout, Belgium.).

#### *Plasmid cloning and expansion*

Plasmids were prepared using standard procedures. Bacterial stocks were grown in Luria-Broth medium overnight at 37°C. All plasmid preparations were obtained using a GenElute™ HP Endotoxin-Free Plasmid Maxiprep Kit (Sigma) and were quantified using a Nanodrop system. pCMV-SPORT6 plasmids carrying hNkx2.5 cDNAs (Clone ID 5225103) were purchased from Open Biosystem (Huntsville, AL, USA) and used for transfection experiments. Total RNA from wt and GRMD CPCs was extracted using a PureLink RNA mini Kit (Invitrogen, Carlsbad, CA, USA) and genomic DNA was digested using the TURBO DNA-free kit (Ambion). cDNA was synthesized using Superscript Reverse Transcriptase III (Invitrogen, Carlsbad, CA, USA). For RT-PCR, cDNA was amplified using Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA). For qPCR analysis, Fast SYBR® Green Master Mix was diluted with cDNA and primers (0.5 mM final concentration). For cardiac differentiation experiments, qPCR analysis were performed using the primers listed in *Table 1B*. For myogenic differentiation 1 (MyoD1) and myogenic factor 5 (Myf5) expression primer sets listed below were used for qPCR analysis:

#### *MyoD1 (Gene ID 611940)*

Fw 5'- AGCAAAGTCAACGAGGCTTTCGAG -3'

Rv 5'- ACCTTCGATGTAGCGAATCGCGTTG -3'

#### *Myf5 (Gene ID 482582)*

Fw 5'- CTACTGTCCTGATGGGCCAAATGT -3'

Rv 5'- GTTGCTCGGAGTTGGTGATTCGAT -3'

Small RNAs were extracted from cell cultures following differentiation using a mirVana kit (Ambion, Austin, TX, US). miRNAs were retrotranscribed using TaqMan® MicroRNA

Reverse Transcription Kit (Applied Biosystem, Foster City, CA, USA) with a specific probe annealing the miRNA of interest. Taqman qPCR was performed using TaqMan® Universal PCR Master Mix, No AmpErase® UNG (Applied Biosystem, Foster City, CA, USA) with specific probe sets.

### *In vitro differentiation*

For cardiac differentiation assays, starvation experiments were performed by shifting cells from MegaCell growth medium to DMEM with 2% horse serum for 14 days. Differentiation with chemical treatment was induced by treating cells with 10  $\mu$ M 5'-Azacytidine (Sigma-Aldrich, St.Louis, MO, US), in differentiation medium for 14 days. For human Nkx2.5 overexpression experiments, 24 hours after transfection cells were serum-starved and cultured for 14 days. A co-culture protocol was also tested for induction of cardiac differentiation in adult canine CPCs using rat neonatal cardiomyocytes (CMs). Cardiac CPCs and CMs were cultured at a 1:5 ratio and cultures were shifted to differentiation medium (DMEM supplemented with 2% horse serum). In this case, 7 day co-cultures were fixed and stained with antibodies against myosin (MF20) and lamin A/C. Nuclei were counterstained with DAPI. In case of proliferating experiments CPCs/CMs co-cultures were kept in DMEM with 10% FBS for 2 days and then fixed for immunocytochemistry experiments. Transforming growth factor  $\beta$  (TGF $\beta$ ) treatment (1 ng/ml, Sigma-Aldrich St.Louis, MO, US) for 7 days was used for smooth muscle induction. Adipogenic and osteogenic assays were performed using Mesenchymal Adipogenesis or Osteogenesis kit from Chemicon (Millipore, MA, US). For osteogenic differentiation, hBMP2 (human bone morphogenetic protein; 50 ng/ml, Sigma-Aldrich, St.Louis, MO, US) was added. Briefly,  $1 \times 10^5$  CPCs were seeded in 6-well dishes and cultivated in conditioned media for 1 month according to the manufacturer's protocol. At differentiation endpoints cells were stained with Red Oil O or Alizarin Red to assay

adipogenic or osteogenic differentiation, respectively. For endothelial commitment,  $5 \times 10^5$  were cultured in ECMatrix<sup>TM</sup> from the In vitro Angiogenesis Assay Kit according to the manufacturer's protocol (Chemicon Millipore, MA, US) and stained for endothelial commitment. For skeletal muscle differentiation, wt or GRMD Ven CPCs were co-cultured in a 1:5 ratio with C2C12 myoblasts and cultured in serum starvation conditions.

### *In vivo experiment*

Severe combined immunodeficient (SCID)/Beige mice and CD1 pregnant rats were purchased from Charles River Laboratories (Wilmington, MA, US). SCID/Beige mice (10 weeks old) were time-mated to obtain neonates of known gestational age. All animal procedures were carried out under "Biosafety Level 2" conditions approved by the Biosafety Committee of the Katholieke Universiteit Leuven and conform to Directive 2010/63/EU of the European Parliament. All neonatal injections were performed within the first 24-36 h of life. The mother of each litter (singly housed) was removed from the cage and pups placed briefly on a bed of ice for anaesthesia. A light source was used to visualize thoracic area and the 20 µl volume containing  $2.5 \times 10^5$  Ven CPCs was administered slowly intraventricularly using a 33-gauge needle and syringe by subxiphoid approach. For identification of injected animals from their non-injected littermates, specific areas of each injected pup was marked by subcutaneous injection of approximately 1 µl of colloidal carbon suspension immediately following stem cell administration. For golden retrievers carrying the GRMD mutation, research was performed according to the principles outlined in the Guide for Laboratory Animal Facilities and Care. Research protocols and facilities were approved by the Animal Care and Use Committee of the Veterinary School of Alfort (Paris, France). For cardiac biopsy isolation, all dogs were maintained until natural death, at which time deceased animals underwent necropsy.

*Statistical analysis*

Values are expressed as mean  $\pm$  S.E.M. When two groups were compared, an unpaired Student's t-test was used. A probability of less than 5% ( $p < 0.05$ ) was considered to be statistically significant. When three groups were compared, and a two-way ANOVA was used, a probability of less than 5% ( $p < 0.05$ ) was considered to be statistically significant (Bonferroni post-test). Statistical significance of the differences between the percentage values was assessed by the Kruskal-Wallis one-way analysis of variance (ANOVA) on ranks, with a Dunn post-hoc test.  $\alpha$  represents the significance in each independent case.  $\alpha < 0.05$  was considered statistically significant.



## RESULTS

### *In vitro isolation and phenotypic characterization*

Heart biopsies obtained from different regions (atrium, aorta and ventricles) of wt and GRMD dogs (*Figure 1A, B*) were cut in small pieces and plated in 1% gelatin or collagen coated dishes (50). Donor age ranged from 12-18 months for wt dogs, while GRMD dogs were, at maximum, six months old (*Table 2A*) (16). At 7-10 days, bright round cells loosely adhering upon a fibroblast feeder layer (*Figure 1C, D*) were collected and expanded in MegaCell medium. Cell outgrowth was observed from biopsies originating from the aorta (Ao), atrium (At) and Ven. Collagen and gelatin coating promoted cell outgrowth at similar levels (*data not shown*). Floating cells were successfully cloned by serial dilution and different clones from wt and GRMD biopsies were further characterized in terms of proliferative ability and gene profile expression. At low density, cells acquired homogenous spindle morphology and required a gelatin coating for complete adhesion to plastic dishes (*Figure 1E, F*). After 3 or 4 days, cell clones cultures became confluent and required passaging, as indicated in the methods section (*Figure 1G, H*). Initially, these clones were characterized for the expression of AP as pericyte marker. AP signal was also detected from outgrowing cells in fresh explants of wt and GRMD biopsies (*Figure 1I, J*). In both low (*Figure 1K, L*) and high (*Figure 1M, N*) density cultures, more than 70% of cells were positive for AP, however, there were no detectable differences between wt and GRMD cells.

### *Characterization of surface markers and gene expression profile*

Adult cell clones were analyzed by RT-PCR for the expression of early cardiac and mesodermal markers. RNA was extracted from wt and GRMD clones derived from At, Ao and Ven regions. Notably, four clones per cardiac region were characterized from individual

wt and GRMD dogs with a very high degree of homogeneity in terms of marker expression profile between clones of the same region (*Table 2B,C*). A strong network of cardiac gene expression has been observed in wt and to a lesser extent in GRMD clones. As previously reported (12,60), early cardiac markers such as Gata4, Gata6 and heart and neural crest derivatives expressed 2 (Hand2) mRNAs are expressed by both proliferating wt and GRMD Ven clones (*Table 2B,C*). Furthermore, wt and GRMD Ven clones expressed the transcription factors myocyte enhancer factor 2A (Mef2A) and Mef2C that are involved in myocyte differentiation and stress signaling (6,35). Previous studies reported the early mesodermal genes Flk1 and cKit act as markers of cardiac progenitor cells (5). Both Flk1 (fetal liver kinase, also known as VEGF receptor 2) and cKit were expressed in our Ao and Ven-derived clones (*Table 2B,C*). Endogenous Nkx2.5 expression has never been detected in proliferating clones (both at mRNA and protein levels) independently from pathological conditions. In sub-confluent cultures, wt and GRMD Ven clones expressed the pericyte markers platelet derived growth factor receptor  $\alpha$  (PDGFR $\alpha$ ), PDGFR $\beta$ , NG2 (chondroitin sulfate proteoglycan 4) and alpha smooth muscle actin ( $\alpha$ SMA), as detected by western blotting and immunofluorescence analysis (*Figure 2A-D*). Wt and GRMD clones also homogeneously expressed GATA4 at the protein level, as detected by immunofluorescence (IF) analysis (*Figure 2E-F*). Interestingly, serial dilution cloning allows the removal of endothelial, smooth muscle cells and fibroblast contaminations, detected only in the polyclonal populations but not in the corresponding clones (*Table 3*). Due to their wide range of early cardiac and pericyte marker expression, we focus our analysis on the ventricle-derived clones of wt and GRMD animals. Nonetheless, considering the similarities in terms of cell morphology and gene expression profile to cardiac progenitor cells as previously reported (1,4,20,29,31,41), we operationally termed our cells “canine cardiac progenitor cells” (CPCs).



*Proliferative capacity and telomerase assay*

Proliferative capacity of wt and GRMD ventricle clones was examined by monitoring PD and by measuring telomerase activity. Considerable differences were observed between wt and GRMD Ven CPCs. On average wt cells were expanded for more than 50 PD in culture whereas GRMD CPCs underwent senescence earlier (40 PD), showing a limited lifespan. Senescent cells can be easily identified as they acquire a distinct fibroblastic shape with a flat, spindle morphology. PD analysis was consistent with these observations with GRMD Ven CPCs displaying a slower proliferation rate at all the PD analyzed (*Figure 2G*). After 15 PD, GRMD Ven CPCs showed a slower proliferation rate compared with wt cells, differing by 18 hours (*Figure 2G, compare blue with red bars*). By contrast, wt cells exhibited a prolonged lifespan and faster proliferation rate (average doubling time 31 hours) compared with GRMD Ven CPCs. This impairment of proliferation was more evident at later doublings where GRMD Ven CPCs reached senescence and wt progenitors were still actively dividing with a doubling time of 62 hours. As high telomerase activity is known to sustain cell proliferation and circumvent replicative senescence (21), we examined telomerase activity in wt and GRMD Ven CPCs and calculated the log copy number of telomeric sequences at different doublings. In agreement with previous observations, telomeric copy number variation encompassed the proliferative defect of GRMD progenitors. Telomerase activity of GRMD Ven CPCs dramatically declined after 15 doublings and became barely detectable after 40 PD (*Figure 2H, red line*). In contrast, telomerase levels in wt Ven CPCs declined gradually, but were still detectable after 40 doublings when GRMD cells had ceased replicating (*Figure 2H, compare blue with red lines*). Telomerase levels in wt Ven CPCs were significantly decreased only after 50 doublings, supporting the results obtained from proliferation analysis.



### *Mesodermal differentiation potential*

To assess the *in vitro* potential of Ven CPCs to convert into mesodermal cell types, subconfluent clones at various PD were cultured in media known to induce specific cell differentiation. During the proliferative phase, both wt and GRMD Ven CPCs lacked expression of key regulators of myogenic commitment, such as MyoD1 and Myf5 (15) (*Figure 3A*). Consequently, Ven CPCs in serum starvation conditions did not spontaneously form myotubes or fuse with C2C12 myoblasts, confirming impairment of skeletal myogenic commitment (*Figure 3B, C*). Augmenting the neovascularization in response to coronary heart diseases represents a major challenge for cell-based therapies. Towards this aim, endothelial commitment of healthy and GRMD Ven CPCs was examined by culturing cells in solid 3-dimensional scaffolds enriched in various proteins (*see In vitro differentiation*). Three days after seeding, wt and GRMD Ven CPCs rapidly aligned and formed hollow tube-like structures identical to those of differentiated HUVEC cells (*Figure 3D-E*). Moreover, IF analysis confirmed the robust endothelial commitment of Ven CPCs showing expression of mature endothelial markers such as CD31 (Platelet endothelial cell adhesion molecule; PECAM) (*Figure 3F, G*) and acLDL uptake ability (*Figure 3H, I*). It is noteworthy that Ven CPCs started to express CD31 only upon differentiation and not during the proliferative state (*data not shown*). Wt and GRMD Ven CPCs also showed the ability to differentiate into smooth muscle cells when treated with TGF- $\beta$ . The dystrophic condition did not interfere with smooth muscle differentiation and when stimulated approximately 50% of cells expressed mature smooth muscle markers such as Calponin and L-Caldesmon (*Figure 3J, K*). Furthermore, adult canine CPCs could differentiate into adipocytes (40% of the total population) when cultured under specific conditions. Both wt and GRMD Ven CPCs formed small Red Oil O-stainable lipid droplets into the cytoplasmic compartment (*Figure 3L, M*). However, these cells do not express the osteogenic marker Runt-related transcription factor 2

(Runx2) (*Table 2B, C*) and consequentially failed to differentiate into mineralized osteocytes as confirmed by absence of alizarin red staining (*Figure 3N, O*).

### *Cardiac differentiation*

We evaluated the ability of canine CPCs to undergo cardiac differentiation by testing several differentiation protocols. In addition to the classical differentiation protocol of serum starvation with or without addition of 5-Azacytidine (5-Aza) (11,25), we also overexpressed hNkx2.5 in these cells by transient transfection. Direct comparison of the differentiation rate between wt and GRMD Ven CPCs was performed in order to highlight the discrepancy in stemness between these cells. Expression of late cardiac markers at differentiation endpoint was examined by immunofluorescence and qPCR analysis, the latter taking advantage of primer sets that specifically recognize canine sequences (*Table 1B*). With these primers, GATA4, cardiac myosin heavy chain (cMyHC) and cardiac Troponin I (cTnI) expression was not detected in mice heart tissue and rat neonatal cardiomyocytes since those primer sets do not recognize the murine or rat version of these genes (*Data not shown*). When proliferating, wt and GRMD Ven CPCs actively expressed GATA4, but no late cardiac markers (*Figure 4A*). When Ven CPCs were exposed to cardiac differentiation medium (low serum) they initiated cardiac differentiation (*Figure 4B*), to varying extents between wt and GRMD progenitors (*compare Figure 4C and D*). In fact, qPCR analysis showed 10-fold upregulation of GATA4 and cMyHC in wt compared with GRMD Ven CPCs (*Figure 4E*). Under these conditions we obtained differentiation rates of 35% and 23% for wt and GRMD progenitors, respectively (*Figure 4B*). 5-Aza treatment increased the overall number of differentiated cells (*Figure 4F, G*) as confirmed also by qPCR analysis for late differentiation markers (*Figure 4H*), resulting in approximately 55%  $\alpha$ SA and cTnI positive wt cells and only 30% positive GRMD Ven CPCs. Due to the lack of endogenous Nkx2.5 expression in both proliferating wt

and GRMD CPCs (*previously mentioned, see Table 2B, C*), we thought to enhance the cardiac differentiation rate by genetically restoring its expression. Human and canine sequences of Nkx2.5 strongly overlap, with a 95% protein homology (*Data not shown*). Transfection efficiency was comparable between wt and GRMD Ven CPCs as hNkx2.5 expression levels were not significantly different when measured 48 hours after transfection (wt  $\Delta\Delta Ct=1.23\pm0.43$  vs. GRMD  $\Delta\Delta Ct=1.02\pm0.11$ , *data not shown*). Transient overexpression of human Nkx2.5 (hNkx2.5) resulted in the most efficient cardiac differentiation of all methods tested with 70%  $\alpha SA^+/cTnI^+$  cells present in wt Ven CPC cultures (*Figure 4I*). Under the same conditions, cardiac commitment of GRMD Ven CPCs was lower and comparable with the 5-Aza protocol (about 35%), suggesting that GRMD Ven CPCs are insensitive to hNkx2.5 overexpression (*compare Figure 4I and J*). Upon this condition, Ven CPCs tend to form cellular structures comparable with rat neonatal cardiomyocytes (*Figure 4K*). The cardiac inductive effect of hNkx2.5 overexpression was confirmed by qPCR analysis, showing robust upregulation of cMyHC and cTnI only in wt Ven CPCs. In fact, cMyHC and cTnI levels in wt Ven CPCs were 15- and 20-fold higher than in GRMD progenitors, respectively (*Figure 4L*). As documented by western blot analysis, only terminally differentiated wt Ven CPCs can express dystrophin as an hallmark of cardiomyogenesis contribution. As expected, the GRMD Ven counterpart failed to express of the structural protein (*Figure 4M*).

#### *miRNA profiling during cardiac differentiation*

We further analyzed the microRNA (miRNA) expression profile during cardiac differentiation, focusing our attention on miRNAs involved in cardiomyogenic and fibrotic events (8,33). miR-208, miR-1 and -133a are involved in cardiac commitment and their expression is regulated by  $\alpha MyHC$  and MEF2A respectively (9,24,55). miR-21 is known to regulate the extent of interstitial fibrosis and cardiac hypertrophy (49), whereas miR-206

expression is restricted to the skeletal muscle system (26). miRNA expression levels were compared between wt and GRMD Ven CPCs during proliferation, serum starvation and transient hNkx2.5 overexpression. Myo-miR-206 expression was never detected in wt and GRMD CPCs confirming the lack of skeletal muscle commitment (*data not shown*). During the proliferative state, expression of miR-133a and miR-1 was slightly higher in wt than in GRMD Ven CPCs (*Figure 5A, white bars*) whereas miR-208 expression was barely detectable in both CPCs. However, serum starvation (*Figure 5A, red bars*) and forced hNkx2.5 expression (*Figure 5A, blue bars*) strongly activated miR-133a, miR-1 and miR-208 expression only in wt Ven CPCs. In the case of hNkx2.5 overexpression, myosin-dependent miR-208, miR-133a, miR-1 were robustly overexpressed (9- to 10-fold) in wt compared with GRMD Ven CPCs. Interestingly, GRMD Ven CPCs had markedly higher miR-21 expression than wt in all the protocols tested, with levels ranging from 5- to 10-fold higher (*Figure 5A*). This miRNA expression profile thus confirms the greater cardiac commitment of wt Ven CPCs and further highlights the diminished plasticity of GRMD Ven CPCs towards cardiomyogenic fate.

#### *Paracrine effects of CPCs*

A key advantage of cell transplantation compared with protein or gene therapy is that donor cells may also alleviate chronic heart dysfunction by stably releasing angiogenic and pro-survival factors (28,30). Moreover, cell-cell contacts or secretion of humoral factors may facilitate the dedifferentiation process and cell cycle re-entry of endogenous cardiomyocytes, an event frequently coupled with cardiac regeneration in newt and zebrafish and that could support cardiac healing also in mammals during post-natal life (42,58). To test this hypothesis, we transduced wt and GRMD Ven CPCs with a GFP-expressing lentiviral vector. FACS-based sorting was performed to enrich the GFP<sup>+</sup> fraction of wt and GRMD Ven CPCs

and rat neonatal cardiomyocytes (99% pure population) were co-cultured together with GFP<sup>+</sup> Ven CPCs to determine to what extent rat cardiomyocyte dedifferentiation occurred. Ki67 reactivity was observed in many GFP negative cells, representing actively proliferating rat cardiomyocytes (*Figure 5B, C*). In this condition  $18 \pm 2.3\%$  and  $11.3 \pm 0.7\%$  of primary rat cardiomyocytes were Ki67 positive when co-cultured with wt or GRMD Ven CPCs, respectively (*Figure 5D, blue and red bars*). In our hands the dedifferentiation rate of rat cardiomyocytes alone was  $2 \pm 1\%$  (*Figure 5D, grey bar*). Next we aimed to establish whether our cells could potentially act as paracrine mediators of cell survival and increase angiogenesis. Pro-angiogenic factors, such as VEGF and bFGF, were measured by ELISA assay in the media of proliferating wt and GRMD CPCs. Indeed, we found similar expression levels of both growth factors by wt and GRMD Ven CPCs (*Figure 5E*). The activation of hepatocyte growth factor (HGF) and insulin-like growth factor-1 (IGF-1) networks provides a selective advantage to cardiac progenitors enabling them to counteract post-ischemic cardiac degeneration (31). The HGF-cMet system is implicated in cell migration and to a lesser extent, in cell growth and survival, whereas IGF-1/IGFR-1 has a predominant effect on cell multiplication and viability (7,57). For this reason we analyzed the expression of these factors in our cells by qPCR. Both wt and GRMD Ven CPCs expressed high levels of cMet, HGF and IGFR-1 during their proliferative state (*Figure 5F*). Altogether these results indicate that Ven CPCs may activate paracrine signaling in acute or chronic cardiac dysfunctions by promoting anti-apoptotic and pro-angiogenic effects.

#### *In vivo regeneration potential*

To further investigate cardiac commitment of wt and GRMD Ven CPCs, we tested their *in vivo* ability to participate in cardiomyogenesis and colonize hearts of neonatal immunodeficient mice. It has been recently reported that the mammalian heart appears to

have a great plasticity within a brief period after birth (42). Due to this strong regenerative capacity, the 1 day-old mouse heart can be considered as a useful model to explore the *in vivo* cardiomyogenic potential of our Ven CPCs. We took advantage of the *piggy-bac* transposon system to genetically label CPCs with nuclear red fluorescent protein (dsRed) to allow an easy and precise *in vivo* identification of canine integrated cells in the host myocardium (Figure 6A). To our knowledge, canine genome editing by transposon technology has never been described in the literature nor has it been used for marking CPCs. Therefore, our approach represents the first attempt to use this novel non-viral technology in cardiac cell therapy and *in vivo* tracing. Nuclear tagging enables easy identification of transplanted cells allowing for better discrimination of fusion events between donor cells and resident cardiomyocytes. *In vivo* experiments were performed with Ven CPCs clones due to their higher cardiac differentiation potency, as previously demonstrated *in vitro*. Following double transfection with transposase (TS) and transposon (TN) -carrying plasmids, approximately 25% of the cells were positive for nuclear dsRed expression (Figure 6B, C). Although only 0.5-1% of the cells stably expressed the dsRed transposon element after a few doublings (Figure 6D, E), they could be enriched by FACS to achieve up to 99% dsRed<sup>+</sup> cellular fractions (Figure 6F, G). No striking differences were observed in terms of transposon integration between wt and GRMD Ven CPCs (Figure 6H-I). Sorted cells maintained the morphology and proliferation ability of non-labeled cells and were easily expanded to a suitable number for transplantation experiments in a large animal model (Figure 7A, B). Moreover, dsRed<sup>+</sup> CPCs retained the ability to differentiate into cardiomyocyte-like cells, as demonstrated by late cardiac markers expression in serum starvation conditions (Figure 7C-F). 2.5x10<sup>5</sup> dsRed<sup>+</sup> wt or GRMD Ven CPCs were injected directly in the cardiac wall of 1-day old SCID/Beige pups (Figure 8A). As a negative control we included a cohort of mice treated with an equal cell number of dsRed<sup>+</sup> wt canine skin fibroblasts. At 1-month post



injection, we analyzed CPCs integration in the host cardiac system by immunolabeling with dsRed and  $\alpha$ SA antibodies. All the animals survived the experimental procedures except for one animal that died within 24 hours of cell injection. At the time of dissection, all transplanted hearts appeared morphologically and functionally normal (*data not shown*). As shown in *Figure 8*, wt and GRMD Ven CPCs colonize the cardiac system by forming new  $\alpha$ SA<sup>+</sup> cardiomyocytes (*Figure 8B, C*). Nuclear dsRed expression was detected also in cardiac cells positive for myosin heavy chain (*Figure 8D, E*) confirming the cardiomyogenic fate of wt and GRMD Ven CPCs. As expected, only wt Ven CPCs contributed to dystrophin expression in the host myocardium (*Figure 8F*) whereas GRMD CPCs failed to express this protein (*Figure 8G*). As a further confirm of their cardiomyogenic potential, we detected dsRed<sup>+</sup>/Cx43<sup>+</sup> cells in both mice treated with wt or GRMD Ven CPCs (*Figure 8H, I*). To confirm that dsRed signal was specific for exogenous canine cells, nuclear co-localization of dsRed and lamin A/C expression were examined in both wt and GRMD Ven CPCs (*Figure 8J, K*). However, GRMD Ven CPCs contributed to cardiomyogenesis to a lower extent than the wt counterpart, as revealed by percentage quantification of double MyHC<sup>+</sup>/dsRed<sup>+</sup> cells ( $24.7 \pm 4.34\%$  wt vs.  $14.44 \pm 3.64\%$  GRMD, *yellow fractions in circle graphs, Figure 8L*). *In vivo* transplantation of GRMD Ven CPCs augments the pool of MyHC<sup>+</sup>/dsRed<sup>+</sup> cells ( $2.11 \pm 1.02\%$  wt vs.  $4.41 \pm 0.87\%$  GRMD, *red fractions in circle graphs, Figure 8L*), which most likely corresponds to interstitial cells. It is important to mention that the quantitative analysis has been performed only on tissue sections corresponding to regions proximal to the injection site. When considering the total amount of cells engrafted per single heart,  $1875 \pm 15$  wt Ven CPCs were counted in spite of the  $1075 \pm 27$  cells for the GRMD counterpart. Within the pool of engrafted cells, wt Ven CPCs contributed to the higher number of MyHC<sup>+</sup> cells per heart ( $1699 \pm 45$ ) compared with the GRMD counterpart ( $717 \pm 52$ ) (*yellow bars in Figure 8L*). Conversely, the pool of interstitial cells (MyHC<sup>-</sup>) was increased following GRMD Ven

CPCs transplantation ( $336 \pm 21$  GRMD vs.  $176 \pm 33$  wt) (*red bars in Figure 8L*). As expected, injection of canine skin fibroblast increased the percentage of interstitial cells ( $12.83 \pm 3.87\%$ ) without any contribution to newly formed cardiomyocytes. Altogether, these data are consistent with the previous observation for differentiation experiments *in vitro*, highlighting the reduced cardiac potential of CPCs derived from a pathological environment.





## DISCUSSION

In the present study we show that the hearts of wt and GRMD dogs have a pool of progenitor cells (CPCs). We demonstrate that resident canine CPCs can be isolated and genetically manipulated, are self-renewing, clonogenic and paucipotent. However, wt and GRMD Ven CPCs reveal relevant differences in terms of expansion and differentiation ability. While wt cells can be expanded for more than 50 doublings in culture, GRMD CPCs displayed limited lifespan and underwent senescence prematurely at 40 doublings. Senescent cells can be easily identified as they acquire a marked fibroblastic shape with a flat, spindle morphology. Together with these observations, PD analysis highlighted the lower proliferative capacity of GRMD CPCs at all the cell doublings analyzed. These results are consistent with new studies reporting that intrinsic characteristics, such as telomere attrition, are critical to tissue regeneration (44). Considering the broader scientific literature (1,4,20,29,31,41) and the similarities found in terms of marker expression profile with reports from other groups isolating cardiac stem cells, we introduced the term CPCs to indicate cells with cardiogenic commitment. In fact, ventricle clones robustly express both Flk1 and cKit, which are established early markers of stem-cell-ness (5,20,31,41). In addition, wt and GRMD CPCs express NG2,  $\alpha$ SMA, PDGFR $\alpha$  and PDGFR $\beta$ , suggesting pericyte origin. Based on our results, Ven CPCs recapitulate both mesoangioblast and cardiac stem cell markers. The absence of pluripotency genes expression and surface markers such as CD73 and CD105 excludes our cells from definition as cardiac stromal cells (CStCs) (43). The analysis of mesodermal differentiation potential reveals that those cells that were able to differentiate into smooth muscle cells, adipocytes and endothelial cells, failed to generate osteoblasts also when stimulated with BMPs. The endothelial differentiation ability has already been observed in murine cardiac stem cells (20), but in canine cells the phenomenon is more similar to their

human counterpart (19). As expected, all clones promptly responded to TGF $\beta$  by activating a smooth muscle differentiation program. The differentiation of Ven CPCs into myocytes has been tested with different approaches, including co-cultures and genetic manipulation. As expected, only wt but not GRMD Ven CPCs can express dystrophin at differentiation endpoints. Differences in cardiomyogenic potential were observed between wt and GRMD Ven CPCs when using serum starvation, azacytidine treatment and expression of Nkx2.5. Nevertheless, all the protocols tested failed to induce ion channel expression levels and the formation of beating cardiomyocytes. No relevant differences were observed among wt and GRMD Ven CPCs in terms of *in vitro* cardiomyocyte proliferation or growth factor secretion and thus we speculated that these cells would have an equal contribution in terms of paracrine effects. Previous studies featuring resident cardiac stem cells that are capable of repairing the infarcted heart have been viewed with skepticism and still some questions remain. In fact, the poor capability of cardiac regeneration during acute ischemic events, in which the scar tissue formation is predominant, places doubt on the value of resident stem cells in the myocardium. Thus, evaluating the differentiation potential of CPCs in an animal model of chronic cardiomyopathy is necessary to understand their functional properties. In this study we provide evidence that the adult canine heart contains a growth reserve that is represented by CPCs. These cells may eventually be coaxed to home to the necrotic area and participate to cardiac regeneration, although this is limited to the surviving portion surrounding the infarcted area (47). In the last few years several stem cell types have been challenged to rescue the phenotype of preclinical models of acute heart damage and resident CPCs have been identified in the heart of mouse, hamster, rat, pig, dog and humans. In this regard, our study advances the field of regenerative cardiology, showing for the first time that CPCs can be isolated from a large animal model of cardiomyopathy. Moreover, the demonstration that cardiac microRNAs, (miR-1, miR-133a and miR-208) are downregulated in GRMD CPCs,

identifies possible therapeutic targets for gene therapy. miR-21 upregulation in GRMD CPCs is also intriguing, since it has recently been shown to be a key element in the fibrotic program of several tissues, including lung (32) and heart (49). It has also been reported that miR-21 positively regulates TGF- $\beta$  signaling by directly targeting SMAD7 (mothers against decapentaplegic homolog 7), explaining at least in part the molecular mechanism of miR-21-mediated fibrosis (34). We identified an upregulation of miR-21 in GRMD Ven CPCs that is consistent with the literature, and consequently, miR-21 could be a potential target to correct undesired fibrotic differentiation events. Additionally, the overexpression of miR-21 in GRMD CPCs raises interesting questions if the scar tissue of an infarcted heart is generated exclusively by the proliferation of connective tissue fibroblasts. We could speculate that the exhaustion of CPC cardiomyogenic potential, due to several attempts to replace damaged cardiomyocytes, leads to a shortened lifespan and an altered differentiation program that is also observed *in vitro* after several doublings. For these reasons, GRMD CPCs may be responsible, at least in part, for scar tissue formation in the cardiomyopathic heart. Nevertheless, cardiac integration of both wt and GRMD CPCs observed in newborn SCID/beige transplanted mice fulfilled their cardiac differentiation potential. As opposed to newborn mice treated with canine fibroblasts, CPCs-treated mice showed normal cardiac architecture compared with sham-operated mice. However, GRMD CPCs failed to functionally integrate in the murine myocardium at comparable levels with wt progenitors, confirming the differentiation impairment observed *in vitro*. In fact, many dsRed<sup>+</sup> nuclei of wt Ven CPCs tend to localize in the dystrophin-positive area of the host myocardium whereas dsRed<sup>+</sup> nuclei coming from GRMD Ven CPCs seem to be outside the dystrophin-positive cells. GRMD CPCs transplantation increases the percentage of donor-derived interstitial cells, presumably due to the activation of an altered fibrogenic program (i.e. overexpression of miR-21). In our opinion, this represents a critical aspect to be considered for a tailored cell therapy

using autologous approaches (23,48,51). An ideal candidate cell for the treatment of muscular dystrophy-related cardiomyopathies is one that has restored expression of a missing gene, such as dystrophin, in this case. In fact, we documented dystrophin expression by wt Ven CPCs both *in vitro* and *in vivo*. Our xenograft *in vivo* study is relevant for two reasons. The first is the demonstration that six month old CPCs still have cardiomyogenic potential *in vivo* and second is the proof of concept that encourages a move towards cell based transplantation protocols that target the GRMD heart. This is a critical issue considering that a clinical trial for muscular dystrophy is currently running after the promising results were obtained after treating GRMD skeletal muscles with mesoangioblasts (45,46).

Until now, the use of circulating progenitors as therapeutic tools has provided good support for paracrine-mediated benefits. The discovery of local cardiac committed stem cells opens a new scenario in terms of cardiac tissue replacement. As these cells tend to disappear from the heart of older (19) or cardiomyopathic mice (14), a therapeutic approach using CPCs should be directed as early as possible to target the necrotic area (59). In fact, for such a diffusely damaged cardiac area, as observed in GRMD dogs or in large trans-mural infarctions, CPCs may not be able to heal the whole area, and neo-angiogenesis and removal of necrotic tissues may be required to allow for correct cell migration. CPCs isolation methods have already been described for mouse (20), human (19) and now for the dystrophic dog and can be applied extensively for the human heart to generate more data regarding committed human cardiac progenitors, moving the field towards tailored cell therapy. This is particularly relevant for progressive pediatric cardiac diseases and to avoid the risks inherent to the systemic mobilization of circulating stem cells, such as homing to non-target organs.

In conclusion, cellular therapies need to become organ-specific and here we accomplished at least three objectives that move the cardiac stem cell field forward. Firstly, we provide evidence that cardiac progenitors can be isolated from a large animal model of cardiac

degeneration, such as the dystrophic GRMD heart. Nonetheless, the use of a stably integrating non-viral gene marking system based on transposons provides a technological improvement that facilitates *in vivo* tracing studies. Finally, the data from the present study provides new insights towards the application of cardiac CPCs for cell therapy of progressive cardiac diseases.



## **ACKNOWLEDGMENTS**

We appreciated Gianpaolo Papaccio and Mark Guns for critical discussion and Shea Carter for editing of the ms. We thank Ermira Samara-Kuko and Rudi Micheletti for the technical assistance, Christina Vochten for the professional secretarial service and Paolo Luban for a kind donation.

## **FUNDINGS**

This work was supported by: the Nash Avery Stem Cell Research–Wicka Fund, University of Minnesota; the Fonds Wetenschappelijk Onderzoek Odysseus Program grant G.0907.08; Research Council of the University of Leuven grant OT/09/053; Cardio Repair European Multidisciplinary Initiative grant 242038 FP7-EC; the Italian Ministry of University and Scientific Research grant 2008RFNT8T\_003 (Progetto di Ricerca di Interesse Nazionale 2008); EC (CARE-MI) FP7-HEALTH-2011.1.4-2-two-stage and Cariplo grants 2007.5639 and 2008.2005 to M. Sampaolesi.

**Disclosure:** the authors declare no potential conflict of interest.

## REFERENCES

1. Assmus, B.; Honold, J.; Schachinger, V.; Britten, M. B.; Fischer-Rasokat, U.; Lehmann, R.; Teupe, C.; Pistorius, K.; Martin, H.; Abolmaali, N. D.; Tonn T.; Dimmeler S.; Zeiher A. M. Transcoronary transplantation of progenitor cells after myocardial infarction. *N. Engl. J. Med.* 355(12):1222-1232; 2006.
2. Backman, E.; Nylander, E. The heart in Duchenne muscular dystrophy: a non-invasive longitudinal study. *Eur. Heart J.* 13(9):1239-1244; 1992.
3. Banks, G. B.; Chamberlain, J. S. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. *Curr. Top. Dev. Biol.* 84:431-453; 2008.
4. Bearzi, C.; Rota, M.; Hosoda, T.; Tillmanns, J.; Nascimbene, A.; De Angelis, A.; Yasuzawa-Amano, S.; Trofimova, I.; Siggins, R. W.; Lecapitaine, N.; Cascapera, S.; Beltrami, A. P.; D'Alessandro, D. A.; Zias, E.; Quaini, F.; Urbanek, K.; Michler, R. E.; Bolli, R.; Kajstura, J.; Leri, A.; Anversa P. Human cardiac stem cells. *Proc. Natl. Acad. Sci. USA* 104(35):14068-14073; 2007.
5. Beltrami, A. P.; Barlucchi, L.; Torella, D.; Baker, M.; Limana, F.; Chimenti, S.; Kasahara, H.; Rota, M.; Musso, E.; Urbanek, K.; Leri, A.; Kajstura, J.; Nadal-Ginard, B.; Anversa, P. Adult cardiac stem cells are multipotent and support myocardial regeneration. *Cell* 114(6):763-776; 2003.
6. Black, B. L.; Olson, E. N. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. *Annu. Rev. Cell. Dev. Biol.* 14:167-196; 1998.
7. Bottaro, D. P.; Rubin, J. S.; Faleto, D. L.; Chan, A. M.; Kmiecik, T. E.; Vande Woude, G. F.; Aaronson, S. A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science* 251(4995):802-804; 1991.
8. Callis, T. E.; Wang, D. Z. Taking microRNAs to heart. *Trends Mol. Med.* 14(6):254-260; 2008.
9. Chen, J. F.; Mandel, E. M.; Thomson, J. M.; Wu, Q.; Callis, T. E.; Hammond, S. M.; Conlon, F. L.; Wang, D. Z. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. *Nat. Genet.* 38(2):228-233; 2006.
10. Chetboul, V.; Escriou, C.; Tessier, D.; Richard, V.; Pouchelon, J. L.; Thibault, H.; Lallemand, F.; Thuillez, C.; Blot, S.; Derumeaux, G. Tissue Doppler imaging detects early asymptomatic myocardial abnormalities in a dog model of Duchenne's cardiomyopathy. *Eur. Heart J.* 25(21):1934-1939; 2004.
11. Choi, S. C.; Yoon, J.; Shim, W. J.; Ro, Y. M.; Lim, D. S. 5-azacytidine induces cardiac differentiation of P19 embryonic stem cells. *Exp. Mol. Med.* 36(6):515-523; 2004.
12. Cohen, E. D.; Wang, Z.; Lepore, J. J.; Lu, M. M.; Taketo, M. M.; Epstein, D. J.; Morrissey, E. E. Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. *J. Clin. Invest.* 117(7):1794-1804; 2007.
13. Cossu, G.; Sampaolesi, M. New therapies for muscular dystrophy: cautious optimism. *Trends Mol. Med.* 10(10):516-520; 2004.
14. Crippa, S.; Cassano, M.; Messina, G.; Galli, D.; Galvez, B. G.; Curk, T.; Altomare, C.; Ronzoni, F.; Toelen, J.; Gijssbers, R.; Debyser, Z.; Janssens, S.; Zupan, B.; Zaza, A.; Cossu, G.; Sampaolesi, M. miR669a and miR669q prevent skeletal muscle differentiation in postnatal cardiac progenitors. *J. Cell Biol.* 193(7):1197-1212; 2011.
15. Davis, R. L.; Weintraub, H.; Lassar, A. B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* 51(6):987-1000; 1987.



16. Drowley, L.; Okada, M.; Payne, T. R.; Botta, G. P.; Oshima, H.; Keller, B. B.; Tobita, K.; Huard, J. Sex of muscle stem cells does not influence potency for cardiac cell therapy. *Cell Transplant.* 18(10):1137-1146; 2009.
17. Finsterer, J.; Stollberger, C. The heart in human dystrophinopathies. *Cardiology* 99(1):1-19; 2003.
18. Fletcher, S.; Ly, T.; Duff, R. M.; Mc, C. H. J.; Wilton, S. D. Cryptic splicing involving the splice site mutation in the canine model of Duchenne muscular dystrophy. *Neuromuscul. Disord.* 11(3):239-243; 2001.
19. Galvez, B. G.; Covarello, D.; Tolorenzi, R.; Brunelli, S.; Dellavalle, A.; Crippa, S.; Mohammed, S. A.; Scialla, L.; Cuccovillo, I.; Molla, F.; Staszewsky, L.; Maisano, F.; Sampaolesi, M.; Latini, R.; Cossu, G. Human cardiac mesoangioblasts isolated from hypertrophic cardiomyopathies are greatly reduced in proliferation and differentiation potency. *Cardiovasc. Res.* 83(4):707-716; 2009.
20. Galvez, B. G.; Sampaolesi, M.; Barbuti, A.; Crespi, A.; Covarello, D.; Brunelli, S.; Dellavalle, A.; Crippa, S.; Balconi, G.; Cuccovillo, I.; Molla, F.; Staszewsky, L.; Latini, R.; Difrancesco, D.; Cossu, G. Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse ventricle. *Cell Death Differ.* 15(9):1417-1428; 2008.
21. Herbert, B.; Pitts, A. E.; Baker, S. I.; Hamilton, S. E.; Wright, W. E.; Shay, J. W.; Corey, D. R. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. *Proc. Natl. Acad. Sci. USA* 96(25):14276-14281; 1999.
22. Howell, J. M.; Fletcher, S.; Kakulas, B. A.; O'Hara, M.; Lochmuller, H.; Karpati, G. Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. *Neuromuscul. Disord.* 7(5):325-328; 1997.
23. Hutcheson, K. A.; Atkins, B. Z.; Hueman, M. T.; Hopkins, M. B.; Glower, D. D.; Taylor, D. A. Comparison of benefits on myocardial performance of cellular cardiomyoplasty with skeletal myoblasts and fibroblasts. *Cell Transplant.* 9(3):359-368; 2000.
24. Ivey, K. N.; Muth, A.; Arnold, J.; King, F. W.; Yeh, R. F.; Fish, J. E.; Hsiao, E. C.; Schwartz, R. J.; Conklin, B. R.; Bernstein, H. S.; Srivastava, D. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. *Cell Stem Cell* 2(3):219-229; 2008.
25. Jing, D.; Parikh, A.; Tzanakakis, E. S. Cardiac cell generation from encapsulated embryonic stem cells in static and scalable culture systems. *Cell Transplant.* 19(11):1397-1412; 2010.
26. Kim, H. K.; Lee, Y. S.; Sivaprasad, U.; Malhotra, A.; Dutta, A. Muscle-specific microRNA miR-206 promotes muscle differentiation. *J. Cell Biol.* 174(5):677-687; 2006.
27. Kornegay, J. N.; Tuler, S. M.; Miller, D. M.; Levesque, D. C. Muscular dystrophy in a litter of golden retriever dogs. *Muscle Nerve* 11(10):1056-1064; 1988.
28. Laflamme, M. A.; Murry, C. E. Regenerating the heart. *Nat. Biotechnol.* 23(7):845-856; 2005.
29. Laugwitz, K. L.; Moretti, A.; Lam, J.; Gruber, P.; Chen, Y.; Woodard, S.; Lin, L. Z.; Cai, C. L.; Lu, M. M.; Reth, M.; Platoshyn, O.; Yuan, J. X.; Evans, S.; Chien, K. R. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. *Nature* 433(7026):647-653; 2005.
30. Li, T. S.; Mikamo, A.; Takahashi, M.; Suzuki, R.; Ueda, K.; Ikeda, Y.; Matsuzaki, M.; Hamano, K. Comparison of cell therapy and cytokine therapy for functional repair in ischemic and nonischemic heart failure. *Cell Transplant.* 16(4):365-374; 2007.
31. Linke, A.; Muller, P.; Nurzynska, D.; Casarsa, C.; Torella, D.; Nascimbene, A.; Castaldo, C.; Cascapera, S.; Bohm, M.; Quaini, F.; Urbanek, K.; Leri, A.; Hintze, T. H.; Kajstura, J.; Anversa, P. Stem cells in the dog heart are self-renewing, clonogenic, and



multipotent and regenerate infarcted myocardium, improving cardiac function. *Proc. Natl. Acad. Sci. USA* 102(25):8966-8971; 2005.

32. Liu, G.; Friggeri, A.; Yang, Y.; Milosevic, J.; Ding, Q.; Thannickal, V. J.; Kaminski, N.; Abraham, E. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. *J. Exp. Med.* 207(8):1589-1597; 2010.

33. Liu, N.; Olson, E. N. MicroRNA regulatory networks in cardiovascular development. *Dev. Cell* 18(4):510-525; 2010.

34. Marquez, R. T.; Bandyopadhyay, S.; Wendlandt, E. B.; Keck, K.; Hoffer, B. A.; Icardi, M. S.; Christensen, R. N.; Schmidt, W. N.; McCaffrey, A. P. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. *Lab. Invest.* 90(12):1727-1736; 2010.

35. McKinsey, T. A.; Zhang, C. L.; Olson, E. N. MEF2: a calcium-dependent regulator of cell division, differentiation and death. *Trends Biochem. Sci.* 27(1):40-47; 2002.

36. McNally, E. M. New approaches in the therapy of cardiomyopathy in muscular dystrophy. *Annu. Rev. Med.* 58:75-88; 2007.

37. Messina, E.; De Angelis, L.; Frati, G.; Morrone, S.; Chimenti, S.; Fiordaliso, F.; Salio, M.; Battaglia, M.; Latronico, M. V.; Coletta, M.; Vivarelli, E.; Frati, L.; Cossu, G.; Giacomello, A. Isolation and expansion of adult cardiac stem cells from human and murine heart. *Circ. Res.* 95(9):911-921; 2004.

38. Moise, N. S.; Valentine, B. A.; Brown, C. A.; Erb, H. N.; Beck, K. A.; Cooper, B. J.; Gilmour, R. F. Duchenne's cardiomyopathy in a canine model: electrocardiographic and echocardiographic studies. *J. Am. Coll. Cardiol.* 17(3):812-820; 1991.

39. Moretti, A.; Caron, L.; Nakano, A.; Lam, J. T.; Bernshausen, A.; Chen, Y.; Qyang, Y.; Bu, L.; Sasaki, M.; Martin-Puig, S.; Sun, Y.; Evans, S. M.; Laugwitz, K. L.; Chien, K. R. Multipotent embryonic isl1<sup>+</sup> progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. *Cell* 127(6):1151-1165; 2006.

40. Muntoni, F.; Torelli, S.; Ferlini, A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. *Lancet Neurol.* 2(12):731-740; 2003.

41. Oh, H.; Bradfute, S. B.; Gallardo, T. D.; Nakamura, T.; Gaussin, V.; Mishina, Y.; Pocius, J.; Michael, L. H.; Behringer, R. R.; Garry, D. J.; Entman, M. L.; Schneider, M. D. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. *Proc. Natl. Acad. Sci. USA* 100(21):12313-12318; 2003.

42. Porrello, E. R.; Mahmoud, A. I.; Simpson, E.; Hill, J. A.; Richardson, J. A.; Olson, E. N.; Sadek, H. A. Transient regenerative potential of the neonatal mouse heart. *Science* 331(6020):1078-1080; 2011.

43. Rossini, A.; Frati, C.; Lagrasta, C.; Graiani, G.; Scopece, A.; Cavalli, S.; Musso, E.; Baccarin, M.; Di Segni, M.; Fagnoni, F.; Germani, A.; Quaini, E.; Mayr, M.; Xu, Q.; Barbuti, A.; DiFrancesco, D.; Pompilio, G.; Quaini, F.; Gaetano, C.; Capogrossi, M. C. Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin. *Cardiovasc. Res.* 89(3):650-660; 2011.

44. Sacco, A.; Mourkioti, F.; Tran, R.; Choi, J.; Llewellyn, M.; Kraft, P.; Shkreli, M.; Delp, S.; Pomerantz, J. H.; Artandi, S. E.; Blau, H. M. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. *Cell* 143(7):1059-1071; 2010.

45. Sampaolesi, M.; Blot, S.; D'Antona, G.; Granger, N.; Tonlorenzi, R.; Innocenzi, A.; Mognol, P.; Thibaud, J. L.; Galvez, B. G.; Barthelemy, I.; Perani, L.; Mantero, S.; Guttinger, M.; Pansarasa, O.; Rinaldi, C.; Cusella De Angelis, M. G.; Torrente, Y.; Bordignon, C.; Bottinelli, R.; Cossu, G. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. *Nature* 444(7119):574-579; 2006.

46. Sampaolesi, M.; Torrente, Y.; Innocenzi, A.; Tonlorenzi, R.; D'Antona, G.; Pellegrino, M. A.; Barresi, R.; Bresolin, N.; De Angelis, M. G.; Campbell, K. P.; Bottinelli, R.; Cossu, G. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. *Science* 301(5632):487-492; 2003.
47. Seidel, M.; Borczynska, A.; Rozwadowska, N.; Kurpysz, M. Cell-based therapy for heart failure: skeletal myoblasts. *Cell Transplant.* 18(7):695-707; 2009.
48. Sherman, W.; He, K. L.; Yi, G. H.; Wang, J.; Harvey, J.; Lee, M. J.; Haimes, H.; Lee, P.; Miranda, E.; Kanwal, S.; Burkhoff, D. Myoblast transfer in ischemic heart failure: effects on rhythm stability. *Cell Transplant.* 18(3):333-341; 2009.
49. Thum, T.; Gross, C.; Fiedler, J.; Fischer, T.; Kissler, S.; Bussen, M.; Galuppo, P.; Just, S.; Rottbauer, W.; Frantz, S.; Castoldi, M.; Soutschek, J.; Koteliensky, V.; Rosenwald, A.; Basson, M. A.; Licht, J. D.; Pena, J. T.; Rouhanifard, S. H.; Muckenthaler, M. U.; Tuschl, T.; Martin, G. R.; Bauersachs, J.; Engelhardt, S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature* 456(7224):980-984; 2008.
50. Tonlorenzi, R.; Dellavalle, A.; Schnapp, E.; Cossu, G.; Sampaolesi, M. Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues. *Curr. Protoc. Stem Cell Biol.* Chapter 2:Unit 2B 1; 2007.
51. Torrente, Y.; Belicchi, M.; Marchesi, C.; Dantona, G.; Cogiamanian, F.; Pisati, F.; Gavina, M.; Giordano, R.; Tonlorenzi, R.; Fagiolari, G.; Lamperti, C.; Porretti, L.; Lopa, R.; Sampaolesi, M.; Vicentini, L.; Grimoldi, N.; Tiberio, F.; Songa, V.; Baratta, P.; Prella, A.; Forzenigo, L.; Guglieri, M.; Pansarasa, O.; Rinaldi, C.; Mouly, V.; Butler-Browne, G. S.; Comi, G. P.; Biondetti, P.; Moggio, M.; Gaini, S. M.; Stocchetti, N.; Priori, A.; D'Angelo, M. G.; Turconi, A.; Bottinelli, R.; Cossu, G.; Rebulli, P.; Bresolin, N. Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. *Cell Transplant.* 16(6):563-577; 2007.
52. Townsend, D.; Yasuda, S.; Chamberlain, J.; Metzger, J. M. Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy. *Trends Cardiovasc. Med.* 19(2):50-55; 2009.
53. Townsend, D.; Yasuda, S.; Li, S.; Chamberlain, J. S.; Metzger, J. M. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. *Mol. Ther.* 16(5):832-835; 2008.
54. Valentine, B. A.; Cummings, J. F.; Cooper, B. J. Development of Duchenne-type cardiomyopathy. Morphologic studies in a canine model. *Am. J. Pathol.* 135(4):671-678; 1989.
55. van Rooij, E.; Sutherland, L. B.; Qi, X.; Richardson, J. A.; Hill, J.; Olson, E. N. Control of stress-dependent cardiac growth and gene expression by a microRNA. *Science* 316(5824):575-579; 2007.
56. Walcher, T.; Kunze, M.; Steinbach, P.; Sperfeld, A. D.; Burgstahler, C.; Hombach, V.; Torzewski, J. Cardiac involvement in a female carrier of Duchenne muscular dystrophy. *Int. J. Cardiol.* 138(3):302-305; 2010.
57. Wang, L.; Ma, W.; Markovich, R.; Chen, J. W.; Wang, P. H. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. *Circ. Res.* 83(5):516-522; 1998.
58. Zaglia, T.; Dedja, A.; Candiotti, C.; Cozzi, E.; Schiaffino, S.; Ausoni, S. Cardiac interstitial cells express GATA4 and control dedifferentiation and cell cycle re-entry of adult cardiomyocytes. *J. Mol. Cell. Cardiol.* 46(5):653-662; 2009.
59. Zhao, M.; Barron, M. R.; Li, Z.; Koprowski, S.; Hall, C. L.; Lough, J. Making stem cells infarct avid. *Cell Transplant.* 19(2):245-250; 2010.

60. Zhao, R.; Watt, A. J.; Battle, M. A.; Li, J.; Bondow, B. J.; Duncan, S. A. Loss of both GATA4 and GATA6 blocks cardiac myocyte differentiation and results in acardia in mice. *Dev. Biol.* 317(2):614-619; 2008.



## FIGURE LEGENDS

### **Figure 1 Morphological characterization of canine cardiac progenitors isolated from different heart regions.**

A-B) DAB staining for dystrophin expression in cardiac tissue sections from wild type (wt) (A) and Golden Retriever Muscular Dystrophy (GRMD) (B) dogs. Scale bars equal to 100  $\mu\text{m}$

C-H) Phase contrast (PhCo) images of cellular outgrowth from wt (C) and GRMD (D) cardiac biopsies showed small bright cells underlying a layer of fibroblast feeder, representing putative cardiac progenitors (CPCs). In middle and lower panels are represented PhCo images of growing (E, F) and confluent (G, H) wt and GRMD CPCs. I-N) Alkaline phosphatase (AP) staining on outgrowing cells from wt (I) and GRMD (J) cardiac explants. At mid-confluency (K, L) and full confluency (M, N) stages, the bulk population contains a pool of  $\text{AP}^+$  cells (about 60-70%) that are maintained during culturing. Scale bar equals to 100  $\mu\text{m}$  for C-D and I-J and equals to 50  $\mu\text{m}$  for E-H and K-N. Data presented are from three independent experiments.

### **Figure 2 Markers expression profile of CPCs.**

A-B) Immunofluorescence (IF) analysis showing  $\alpha\text{SMA}$  (green) and NG2 (red) expression in wt (A) and GRMD (B) ventricle (Ven) CPCs. Nuclei were counterstained in blue with DAPI. Scale bar equals to 100 $\mu\text{m}$ . Inset scale bar equals to 50  $\mu\text{m}$ . Data presented are from three independent experiments. C-D) IF analysis revealing  $\text{PDGFR}\beta^+$ (red)/ $\text{Ki67}^+$ (green) cells in wt (C) and GRMD (D) Ven CPCs. Nuclei were counterstained in blue with DAPI. Scale bar equals to 100 $\mu\text{m}$ . Inset scale bar equals to 50  $\mu\text{m}$ . Data displayed is representative of three independent experiments. E-F) IF analysis showing GATA4 (red) expression in wt (E) and GRMD (F) Ven CPCs. Nuclei were counterstained in blue with DAPI in E' and F'. Scale bar

equals to 100µm. Inset scale bar equals to 50 µm. Data presented are from three independent experiments. G) PD analysis of freshly isolated wt (blue bars) and GRMD (red bars) Ven CPCs. The proliferative gap increased during time and became evident at 15 doublings. Values are presented as means  $\pm$ SEM (n=5, \* $p$ <0.05 and \*\* $p$ <0.01 wt vs. GRMD). H) Telomeres copy number quantification of wt (blue line) and GRMD (red line) Ven CPCs. Values from atrium (At), aorta (Ao) and Ven clonal populations are presented as means  $\pm$ SEM. (n=5, \* $p$ <0.05 wt vs. GRMD and \*\* $p$ <0.01 wt vs. GRMD).

**Figure 3 *In vitro* differentiation of CPC towards mesodermal lineage.**

A) qPCR analysis for MyoD1 and Myf5 expression in proliferating wt (blue bars) and GRMD (red bars) Ven CPCs. Proliferating C2C12 were used as a positive control (black bars). n=5 \* $p$ <0.01 C2C12 vs. wt \*\* $p$ <0.01 C2C12 vs. GRMD. B-C) Cocultures (ratio 1:5) of murine C2C12 with wt (B) or GRMD (C) Ven CPCs stained for lamin A/C (red) and MyHC (green) expression. Nuclei were counterstained in blue with DAPI. Scale bar equals to 50 µm. Data presented are representative of three independent experiments. D-I) Phase contrast and IF images of Ven CPCs cultured in 3-dimensional ECMatrix<sup>TM</sup> scaffold for 7 days. Cells rapidly assumed hollow tubular-like structures (PhCo; D, E) and were further characterized for CD31 (PECAM; F and G in green) and acLDL (H and I in red) expression as mature markers of endothelial differentiation. Scale bars equal to 100 µm. Data presented are representative of three independent experiments. J-K) 1 week stimulation with TGF- $\beta$  was sufficient to activate smooth muscle program in both wt (J) and GRMD Ven CPCs (K) as highlighted by the presence of cells positive for Calponin (Green) and Caldesmon (red) expression. Nuclei were counterstained in blue with DAPI. Scale bar equal to 100 µm. Data presented are representative of three independent experiments. L-M) Red oil-O staining revealed lipid droplets accumulation both in wt (L) and GRMD progenitors (M) treated for 1 month with

adipogenic-conditioned media. Scale bar equals to 100  $\mu\text{m}$ . Inset scale bar equals to 50  $\mu\text{m}$ . Data presented are representative of three independent experiments. N-O) Ven CPCs cultured for 1 month in hBMP2-conditioned media were counterstained for alizarin red confirming the absence of calcium deposits both in wt (N) and GRMD (O) progenitors. Scale bar equals to 100  $\mu\text{m}$ . Inset scale bar equals to 50  $\mu\text{m}$ . Data presented are representative of three independent experiments.

#### **Figure 4 Cardiac induction of CPCs.**

A) qPCR analysis for early and late cardiac markers in proliferating wt (blue bars) and GRMD (red bars) Ven CPCs. n=3. B) Cardiac differentiation rates of wt (blue bars) and GRMD (red bars) Ven CPC in three differentiation protocols. Cardiac commitment rate was calculated as the ratio of double  $\alpha\text{SA}^+/\text{cTnI}^+$  cells versus the total number of cells. Numbers of experiments performed are indicated within the bars.  $^*\alpha<0.05$ ;  $^{**}\alpha<0.01$ . C-D) Cardiac differentiation of wt (C) and GRMD (D) Ven CPC induced by serum starvation. After 14 days cells were analyzed for the expression of  $\alpha\text{SA}$  (red) as marker of terminal differentiation. Serum starvation condition activates  $\alpha\text{SA}$  expression (red) in differentiated cells. Note that number of  $\alpha\text{SA}^+$  cells resulted always higher in wt than in GRMD CPC (compare C with D). Nuclei were counterstained with DAPI. Scale bar equals to 50  $\mu\text{m}$ . Data displayed are representative of seven independent experiments. E) Fold-induction rate relative to Gata4, cMyHC and cTnI expression of wt versus GRMD progenitors in serum starvation conditions. Expression levels were compared at differentiation endpoint. n=7. F-G) IF staining for  $\alpha\text{SA}$  (red) expression of wt (F) and GRMD (G) Ven CPCs following 5-Azacytidine treatment. Nuclei were counterstained in blue with DAPI. Scale bar equals to 100  $\mu\text{m}$ . Data displayed is representative of five independent experiments. H) Fold-induction rates of Gata4, cMyHC and cTnI expression of wt versus dystrophic progenitors at differentiation endpoint in 5-



Azacytidine treatment. n=5. I-J) Cardiac differentiation analysis of wt (I) and GRMD (J) Ven CPC induced by forced hNkx2.5 expression. After 14 days cells were analyzed for the expression of  $\alpha$ SA (red) as marker of terminal differentiation. Forced hNkx2.5 expression markedly upregulates  $\alpha$ SA expression (red) in differentiated cells. Note that number of  $\alpha$ SA<sup>+</sup> cells resulted always higher in wt than in GRMD CPC (compare I with J). Nuclei were counterstained with DAPI. Scale bar equals to 50  $\mu$ m. Data displayed is representative of seven independent experiments. K) IF staining for  $\alpha$ SA (red) on primary culture of rat neonatal cardiomyocytes. Nuclei were counterstained with DAPI. Scale bar equals to 50  $\mu$ m. L) Fold-induction rate relative to Gata4, cMyHC and cTnI expression of wt versus GRMD progenitors following hNkx2.5 overexpression. Expression levels were compared at differentiation endpoint. n=7. M) Western blot (WB) analysis for dystrophin expression from wt and GRMD Ven CPCs at differentiation endpoints. Canine skeletal muscle as a positive control. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as internal control. n=3.

**Figure 5 microRNA profiling and paracrine release of growth factors.**

A) Relative expression of miRNA133a, -208, -1 and -21 of wt versus GRMD Ven CPCs. miRNAs fold-induction rate was analyzed at different timepoints: during proliferation (white bars), differentiation endpoints in serum starvation (red bars) and hNkx2.5 overexpression (blue bars). All the experiments were performed in triplicates per each clone. B-C) IF staining for GFP (green) and Ki67 (red) of rat neonatal cardiomyocytes co-cultured for 2 days with GFP<sup>+</sup> wt (B) and GRMD (C) Ven CPCs. Nuclei were counterstained in blue with DAPI. Scale bar equals to 100  $\mu$ m. Data are representative of four independent experiments. D) Rate of cardiomyocytes proliferation was calculated as the ratio of Ki67<sup>+</sup>/GFP<sup>-</sup> cells versus the total number of GFP<sup>-</sup> cells. Proliferating rate was analyzed in co-culture conditions with wt (blue

bar) or GRMD (red bar) Ven CPCs. Grey bar (CM) represents proliferating rate of rat neonatal cardiomyocytes alone. Values are presented as means  $\pm$ SEM. (n=4 \* $p$ <0.01 CM+wt vs. CM+GRMD; \*\* $p$ <0.01 CM+wt vs. CM alone). E) bFGF and VEGF secretion in proliferating media of wt (blue bars) and GRMD (red bars) Ven CPCs quantified by ELISA assay. Values are presented as means  $\pm$ SEM. n=4. F) qPCR analysis in growing conditions revealed robust expression of cMet, HGF and IGFR-1 in wt (blue bars) and GRMD (red bars) Ven CPCs. Data presented are from five independent experiments  $\pm$ S.E.M.

### **Figure 6 Genetic labeling and dsRed<sup>+</sup> CPC enrichment.**

A) Schematic representation of transposase plasmid pcDNA3CMV/bGI-PiggyBAC/MTA (left) and transposon plasmid pBac/CMV-ndsRed (right) used for genetic labeling of wt and GRMD Ven CPCs. B-G) Following transfection with the transposase/transposon plasmids, wt (B) and GRMD (C) Ven CPCs were analyzed by IF for nuclear dsRed expression (red). After few PD the pool of wt (D) and GRMD (E) dsRed<sup>+</sup> CPC decreased due to the progressive clean up of transiently transfected cells without transposon integration. Stable integrating dsRed<sup>+</sup> cells were FACS-sorted to obtain a pure bulk of nuclear dsRed<sup>+</sup> wt (F) and GRMD (G) Ven CPCs. Scale bars equal to 100  $\mu$ m. Data displayed is representative of three independent transfection experiments per each clone. H-I) FACS-based sorting of dsRed<sup>+</sup> wt (H) and GRMD (I) Ven CPCs. P1 gates represent the pool of dsRed<sup>+</sup> cells. n=3.

### **Figure 7 Amplification and differentiation capacity of dsRed<sup>+</sup> CPC.**

A) Cell amplification graph of FACS-sorted dsRed<sup>+</sup> Ven wt (blue line) and GRMD (red line) CPC. Data displayed is representative of five independent experiments. \* $p$ <0.01 wt vs. GRMD. B) Population doubling (PD) analysis of FACS-sorted dsRed<sup>+</sup> Ven wt (blue line) and GRMD (red line) CPCs. Transposon integration and cell sorting don't interfere with



proliferative ability of dsRed<sup>+</sup> progenitors that strongly overlaps with non-labeled CPCs. \**p*<0.01 wt vs. GRMD. C-F) IF staining for αSA (green) and dsRed (red) expression on FACS-sorted wt (C-D') and GRMD (E-F') Ven CPCs in starvation condition. Nuclei were counterstained in blue with DAPI. White scale bars equal to 50 μm. Yellow scale bars equal to 25 μm. Data displayed is representative of four independent experiments.

**Figure 8 *In vivo* transplantation of dsRed<sup>+</sup> CPC in neonatal SCID/Beige mice.**

A) Technical scheme for *in vivo* transplantation of CPCs in immunodeficient 1-day old pups. 2.5x10<sup>5</sup> dsRed<sup>+</sup> wt or GRMD Ven CPCs were injected in the cardiac wall of 1-day old SCID/beige pups. Transplanted hearts were collected at 30 days post-injection for the detection of cardiac chimerism of donor cells in the host myocardium. B-G) IF staining for αSA (green in B and C), MyHC (green in D and E), dystrophin (green in F and G) and nuclear dsRed (red) expression in 30 days old SCID/Beige hearts injected with wt (B, D and F) or GRMD (C, E and G) Ven CPCs. Scale bars equal to 100 μm. 20 slides were analyzed per each mice transplanted. H-I) IF staining for connexin 43 (green in H and I) and nuclear dsRed (red) expression on cardiac tissue sections from mice treated with wt (H) and GRMD (I) Ven CPCs. PhCo images are in H' and I'. Scale bar equals to 100 μm. J-K) IF staining on cardiac sections of SCID/Beige mice treated with wt (J) or GRMD (K) Ven CPCs revealing co-localization of nuclear dsRed (red) and lamin A/C (green) signals in canine transplanted cells. Scale bars equal to 30 μm. Nuclei were counterstained in blue with Dapi. 20 slides were analyzed per each mice transplanted. L) Upper circle graphs: percentage quantification of integrating CPCs at 1 month post-transplantation. Only slides containing dsRed<sup>+</sup> cells, most likely corresponding to regions proximal to the injection site, were considered for the analysis. Counted cells were divided in three groups: resident murine cardiomyocytes (green bars), CPCs-derived cardiomyocytes (yellow bars) and interstitial CPCs-derived cells (red

bars). Canine Skin Fibroblasts (Fibs) were used as negative controls. Lower bar graphs: cells quantification of canine-derived cardiomyocytes (yellow bars) or interstitial cells (red bars) per single heart treated with wt, GRMD Ven CPCs or canine skin fibroblasts. Seven mice were analyzed for each group. Values are presented as means  $\pm$ SEM. \*  $p < 0.01$  MyHC<sup>+</sup>/dsRed<sup>+</sup> wt vs. MyHC<sup>+</sup>/dsRed<sup>+</sup> GRMD, \*\*  $p < 0.05$  MyHC<sup>-</sup>/dsRed<sup>+</sup> wt vs. MyHC<sup>-</sup>/dsRed<sup>+</sup> GRMD.






Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

LANTATION  
The Regenerative Medicine Journal




Figure 7




Figure 8

LANTATION  
The Regenerative Medicine Journal

A

Host species	Antibody	# number	Company
Mouse mAb	anti-GAPDH	OBT1636	AbD Serotec
Mouse mAb	anti-alphaSA	ab9465	Abcam
Mouse mAb	anti-cTnI	ab19615	Abcam
Rabbit pAb	anti-Tbx2	ab33298	Abcam
Goat pAb	anti-GFP	ab5450	Abcam
Mouse mAb	anti-MyHC	MF20	DSHB
Mouse mAb	anti-CD31	P2B1	DSHB
Rabbit mAb	anti-PDGFRa	5241	Cell Signaling
Rabbit mAb	anti-PDGFRb	3169	Cell Signaling
Mouse mAb	anti-Dystrophin (Rod)	NCL-DYS1	Novocastra
Mouse mAb	anti-Dystrophin (C-term)	NCL-DYS2	Novocastra
Rabbit pAb	anti-Nkx2.5	5444	Cell Signaling
Mouse mAb	anti-NG2	MAB5384	Millipore
Rabbit pAb	anti-GATA4	sc-9053	Santa Cruz
Rabbit pAb	anti-Caldesmon	sc-7575	Santa Cruz
Rabbit pAb	anti-Cx43	sc-9059	Santa Cruz
Mouse mAb	anti-cKit	sc-365504	Santa Cruz
Goat pAb	anti-dsRed	sc-33354	Santa Cruz
Mouse mAb	anti-Ki67	M7240	Dako
Mouse mAb	anti-Calponin	M3556	Dako
Mouse mAb	anti-SMA	A2547	Sigma-Aldrich
Donkey anti-rabbit	Alexa Fluor® 594	A21207	Molecular Probes
Donkey anti-mouse	Alexa Fluor® 594	A21203	Molecular Probes
Donkey anti-goat	Alexa Fluor® 594	A11058	Molecular Probes
Donkey anti-mouse	Alexa Fluor® 488	A21202	Molecular Probes
Donkey anti-rabbit	Alexa Fluor® 488	A21206	Molecular Probes
Donkey anti-goat	Alexa Fluor® 488	A11055	Molecular Probes

B

Name	Gene ID	Forward	Reverse
Gata4	486079	5'- CAACTCCAGCAATGTGGCCA-3'	5'- CCAGACATCGCACTGACTGA -3'
Myh7	403807	5'- CAGAATGAGATCGAGGACCTCATG -3'	5'- TCCACTGGAACCCAGCTGCTCAGT -3'
cTnI	403566	5'- ACCTTCGTGGCAAATTTAAGCGGC -3'	5'- TGTGTCCTCCTTCTTCACCTGCTT -3'
β-tubulin	474830	5'- CTTCCAGCTGACCCACTCA -3'	5'- TGGTGGCTGAGACAAGGTGGT -3'

**Table 1.** A) List of antibodies used; B) Primer sequences used for species-specific identification of canine transcripts by qPCR in differentiation experiments. None of these primer sets detect a signal from murine heart or rat cardiomyocytes cDNA samples.



A

Table 2

Name	Sex	Age	Clinical status	Biopsy
EOP	Male	6 months	GRMD	At, Ao, Ven
E6	Female	6 months	GRMD	At, Ao, Ven
EXON	Male	6 months	GRMD	Ao, Ven
HERCULES	Male	12 months	Healthy (guide dog trainee)	At, Ven
DEVON	Male	18 months	Healthy (GRMD colony)	At, Ao, Ven
DARIA	Female	15 months	Healthy (GRMD colony)	At, Ao, Ven

B

	At wt #1	At wt #2	At wt #3	At wt #4	Ao wt #1	Ao wt #2	Ao wt #3	Ao wt #4	Ven wt #1	Ven wt #2	Ven wt #3	Ven wt #4
Mef2A (r)	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
Mef2C (r)	Pos	Pos	Pos	Pos	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos
Gata4 (r,p,if)	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
Gata6 (r)	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
Hand2 (r)	Pos	Pos	Pos	Pos	Neg	Pos	Neg	Neg	Pos	Pos	Pos	Pos
Isl1 (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Nkx2.5 (r,p)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Mesp1 (r)	Pos	Neg	Pos	Pos	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos
Tbx2 (p)	Pos	Pos	Pos	Pos	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos
Cx43 (r)	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
Flk1 (r)	Pos	Pos	Neg	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
cKit (r,p)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos
aSMA (p,if)	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
PDGFRa (p,if)	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
PDGFRb (p,if)	Pos	Pos	Pos	Pos	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos
NG2 (p,if)	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
CD146 (f)	Neg	Neg	Neg	Neg	Dim	Dim	Dim	Dim	Dim	Dim	Dim	Dim
CD13 (f)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
CD73 (f)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
CD105 (f)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Oct4 (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Klf4 (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Nanog (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Sox2 (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Runx2 (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg

C	At GRMD #1	At GRMD #2	At GRMD #3	At GRMD #4	Ao GRMD #1	Ao GRMD #2	Ao GRMD #3	Ao GRMD #4	Ven GRMD #1	Ven GRMD #2	Ven GRMD #3	Ven GRMD #4
Mef2A (r)	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
Mef2C (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos
Gata4 (r,p,if)	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
Gata6 (r)	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
Hand2 (r)	Neg	Neg	Neg	Neg	Neg	Neg	Pos	Neg	Pos	Pos	Pos	Pos
Isl1 (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Nkx2.5 (r,p)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Mesp1 (r)	Pos	Pos	Pos	Pos	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos
Tbx2 (p)	Pos	Pos	Pos	Pos	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos
Cx43 (r)	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
Flk1 (r)	Neg	Neg	Neg	Pos	Pos	Neg	Pos	Pos	Pos	Pos	Pos	Pos
cKit (r,p)	Pos	Pos	Pos	Neg	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos
$\alpha$ SMA	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos	Pos
PDGFR $\alpha$ (p,if)	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Neg	Pos	Pos	Pos	Pos
PDGFR $\beta$ (p,if)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos
NG2 (p,if)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos
CD146 (f)	Neg	Neg	Neg	Neg	Dim	Dim	Dim	Neg	Dim	Dim	Dim	Dim
CD13 (f)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
CD73 (f)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
CD105 (f)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Oct4 (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Klf4 (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Nanog (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Sox2 (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
Runx2 (r)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg

**Table 2.** A) Characteristics of the animals used for CPCs isolation. Three healthy control biopsies were obtained from dogs died for natural causes not related with cardiac dysfunction. Three cardiac biopsies were obtained from animals affected by GRMD. B-C) Gene expression profile analysis of proliferating wt and GRMD CPCs clones. r=RT-PCR; p=WB; if= immunofluorescence; f=FACS

A

	Ven Poly wt	Ven clone wt	Ven Poly GRMD	Ven clone GRMD
<b>cKit (r)</b>	Pos	Pos	Pos	Pos
<b>Flk1 (r)</b>	Pos	Pos	Pos	Pos
<b>Nkx2.5(p)</b>	Neg	Neg	Neg	Neg
<b>Mef2A (r)</b>	Pos	Pos	Pos	Pos
<b>Mef2C (r)</b>	Pos	Pos	Pos	Pos
<b>Gata4 (if)</b>	Pos	Pos	Pos	Pos
<b>Gata6 (r)</b>	Pos	Pos	Pos	Pos
<b>CD105 (f)</b>	Pos	Neg	Pos	Neg
<b>CD73 (f)</b>	Pos	Neg	Pos	Neg
<b>Thy1 (f)</b>	Pos	Neg	Pos	Neg
<b>Vimentin (r)</b>	Pos	Neg	Pos	Neg
<b>Calponin (r)</b>	Pos	Neg	Pos	Neg
<b>CD31 (r,p)</b>	Pos	Neg	Pos	Neg
<b>vWF (r)</b>	Pos	Neg	dim	Neg
<b>PPAR-<math>\gamma</math>2 (r)</b>	dim	Neg	dim	Neg

**Table 3.** A) Heterogeneity at gene expression level between polyclonal and clonal populations of wt and GRMD CPCs. r=RT-PCR; p=WB; if =immunofluorescence; f=FACS.